Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Best Veggie lover Dinner: What's Your Plant-Based Pick? - 2An ex-FBI agent analyzes what we learned from Savannah Guthrie's 'Today' show interview amid the search for her mother Nancy
- 3Landon Donovan knew he couldn’t hide his hair loss. So he turned to fans for help.
- 4Eurovision Song Contest changes voting rules after controversial allegations against Israel
- 5the 6 Shrewd Beds for seniors: A Complete Survey
- Find Serenity: 10 Stunning Setting up camp Areas
- Struggling to keep your New Year's resolutions? Here's how to keep yourself on track
- 10 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide
- Flu season is ramping up, and some experts are "pretty worried"
- Study shows no clear link between low-fat dairy and dementia risk
- Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy
- Nearly 16,000 New York City nurses prepare to strike as contract talks stall
- The Best Computer games for Multiplayer Fun
- Death toll from floods in Afghanistan rises to 61
